Combined Use of Vaccination and Immunotherapy Drugs to Achieve a Long-Term Clinical Remission in Patients with Chronic HPV-infection Manifested in condyloma accuminata of the anogenital area

Study objective. The study aims at evaluating the efficacy of combined administration of imiquimod 5% cr me and human papillomavirus (HPV) quadrivalent recombinant vaccine in order to achieve a long-term clinical remission in patients with chronic HPV infection manifested in condyloma accuminata of the anogenital area. Materials and Methods. The study enrolled 36 subjects aged 26.4 (4.1) years (including 22 men) with 1 to 5 condyloma accuminata of the anogenital area. Study participants were vaccinated with human papillomavirus quadrivalent recombinant vaccine using a 0 - 2 - 6 month regimen with concomitant administration of imiquimod 5% cr me applied 3 times per week for not more than 16 weeks. Results. Complete disappearance of condyloma accuminata was observed in 34 out of 36 subjects (94.4%) after one year from the start of treatment. Two patients still having condyloma accuminata of the anogenital area after one year of combination treatment underwent a successful course of treatment with solcoderm (one patient for 1 year 3 months and the other for 1 year 4 months) that resulted in complete disappearance of condyloma accuminata. Within the 1 year 6 month period no recurrence of condyloma accuminata of the anogenital area has been observed. Conclusion. Vaccination with human papillomavirus quadrivalent recombinant vaccine along with concomitant use of imiquimod 5% cr me enables to achieve a long-term clinical remission in patients with chronic HPV infection manifesting in condyloma accuminata of the anogenital area, in at least 94.4% of patients followed up for 1 year 6 months.